$ADGM

Adagio Medical Holdings, Inc. (ADGM): Submission of Matters to a Vote of Security Holders

Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0002006986 0002006986 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Original reporting
Published Jun 16, 2026, 9:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$ADGM
Neutral
high confidence
Mentioned
$ADGM
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ADGMNeutralLow
01

Why it matters

The disclosure confirms corporate governance actions (two director nominees elected; independent auditor ratified) but does not provide new financial performance, guidance, or material corporate events.

02

Market read

Primarily confirms routine governance items; limited trading relevance absent any indication of contested outcomes or strategic shifts.

03

What to watch

The filing does not specify any director changes beyond election/withheld counts, nor does it mention auditor issues; without additional context, the market impact should be treated as limited.

Relevance 6/10Novelty 2/10Timing: Filed June 16, 2026 (post-meeting results)

Background

The company filed an 8-K under Item 5.07 summarizing matters voted on at its June 16, 2026 annual meeting, as described in its April 30, 2026 proxy statement.

Company-level read

Ticker impact

$ADGMNeutralHigh confidence
Context

Adagio Medical Holdings reported 2026 annual meeting voting results, including election of two directors and ratification of its auditor.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to governance/overhang sentiment.

Evidence & confidence

The filing discloses standard proxy vote tallies (director election and auditor ratification) without changes to guidance, strategy, litigation, or material transactions.

Market effects

Minimal; does not introduce new sector-level regulatory or competitive information.

Minimal; single-company corporate governance disclosure.

Minimal; no cross-border transaction or global regulatory development.

Counterpoint

If the vote results were contested, traders might look for follow-on activism or governance changes—but this filing provides no such context beyond the final tallies.

Key entities

  • Adagio Medical Holdings, Inc.

    Subject of the 8-K; reported annual meeting vote results for director election and auditor ratification.

  • WithumSmith+Brown, PC

    Independent registered public accounting firm ratified for the fiscal year ending December 31, 2026.

Related articles

$ADGMMed

Adagio Medical Holdings, Inc. (ADGM): Results of Operations and Financial Condition

Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622801d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagio Medical Reports Second Quarter 2026 Results LAGUNA HILLS, CA, August 11, 2026 – Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for th

$ADGMMedAI 8/10

Adagio Medical Treats First Patient With Next-Generation VCLAS Ultra System; Stock Up

Adagio Medical Holdings (ADGM) said it treated its first patient with its next-generation vCLAS Ultra ultra-low temperature ablation system under FDA expanded access. The patient with non-ischemic cardiomyopathy and prior failed VT ablations was treated at the University of Pennsylvania. Adagio also noted IDE approval for its FULCRUM-VT trial and reported no VT recurrence two months later.

$ADGMMedAI 8/10

Adagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System

Adagio Medical Holdings (Nasdaq: ADGM) said the FDA granted Expanded Access authorization for its next-generation vCLAS Ultra ULTA system, and clinicians at the Hospital of the University of Pennsylvania treated the first patient with ventricular tachycardia after prior failed ablations. The company expects IDE expansion of its FULCRUM-VT trial to assess the system for sustained monomorphic VT.

$ADGMMed

Adagio Treats First Patient with Next

Adagio Medical Holdings Inc. said it treated the first patient with its next-generation vCLAS Ultra low-temperature ablation system. The company claims it can reach -170°C and cut ablation time by 50% to 75%, shortening procedures by up to 30 minutes versus the prior system. Adagio noted the FDA granted IDE approval in April to expand its FULCRUM-VT trial. Shares rose 19% to 45 cents.

$ADGMMedAI 9/10

Adagio Medical Seeks FDA OK for Heart Device

Adagio Medical Holdings submitted a premarket approval (PMA) application to the FDA for its vCLAS Ventricular Ablation System to treat ventricular tachycardia. The filing is supported by six-month Fulcrum-VT IDE trial data: 84% avoided device shocks and 59% had no VT recurrence. Adagio said the system has CE Mark approval; shares trade near $0.75.